TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07308132: A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)

Sponsor: Janssen Research & Development, LLC · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 340 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,220,368

Rescue Site Savings

+$4,115,496

Unlock Full NCT07308132 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07308132 Rescue Dossier →